IDH1 and glioblastoma: Parsons et al. (2008) reported that patients with IDH-mutant GBM had an average survival time of 3.8 years, while the average survival time of IDH1-wild type patients was 1.1 years. These reports indicated that the IDH1 mutation status in patents with GBM was significantly correlated with the prognosis, and that preoperative identification of IDH1 mutations in GBM is of critical prognostic importance.